ADVANCED HEALTH INTELLIGENCE LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.092 AUD | +8.24% |
|
-.--% | -26.40% |
| 18/04 | Advanced Health Intelligence's Loss Widens in H1 FY2024 | MT |
| 18/04 | Advanced Health Intelligence Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Software
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -26.40% | 14.92M | - | - | |
| +24.05% | 23.73B | - | C | |
| +2.71% | 2.46B | D+ | ||
| +99.87% | 2.08B | C- | ||
| -23.48% | 1.84B | - | ||
| -50.54% | 1.52B | - | - | |
| +10.49% | 1.4B | - | ||
| +4.29% | 1.33B | B- | ||
| -14.31% | 1.32B | - | ||
| +14.05% | 1.12B | B- |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- AHI Stock
- Ratings Advanced Health Intelligence Ltd